Common use of Exclusivity of the Project Clause in Contracts

Exclusivity of the Project. 4.1.1 Within three years after the effectiveness of this Agreement, Party B shall not develop monospecific antibodies against the PD-L1 target, nor shall it authorize any third party to the use of any sequences, cell lines, nanobodies, data, patented technology or other items; Any new projects in conflict with the interests of this Project shall be determined by the Parties through consultation and the Parties shall have the prior cooperation right. However, the exclusivity obligation provided for in this Article does not include bispecific antibodies (simultaneously bind two different epitopes), antibody conjugates (ADC), diagnostic antibodies, antibody-targeted nanoparticles (Nano-particles) and antibody prodrugs (Probody).

Exclusivity of the Project. 4.1.1 Within three years after the effectiveness of this Agreement, Party B shall not develop on its own any monospecific antibodies antibody against the PD-L1 target, nor shall it authorize any third party to the use of any sequences, cell lines, nanobodies, data, patented technology or other items; . Any new projects in conflict with the interests of this Project project shall be determined by the Parties Party A and Party B’s Affiliate through consultation and the Parties Party A and Party B’s Affiliate shall have the prior cooperation right. However, the exclusivity obligation provided for in this Article does not include bispecific antibodies (simultaneously bind two different epitopes)antibodies, antibody conjugates (ADC), diagnostic antibodies, antibody-targeted nanoparticles (Nano-particles) and antibody prodrugs (Probody).

Exclusivity of the Project. 4.1.1 Within three years after the effectiveness of this Agreement, Party B shall not develop monospecific antibodies against the PD-L1 [***] target, nor shall it authorize any third party to the use of any sequences, cell lines, nanobodies, data, patented technology or other items; Any new projects in conflict with the interests of this Project shall be determined by the Parties through consultation and the Parties Party A shall have the prior cooperation rightright under the same conditions. However, the exclusivity obligation provided for in this Article does not include bispecific antibodies (simultaneously bind two different epitopes), antibody conjugates (ADC), diagnostic antibodies, antibody-targeted nanoparticles (Nano-particles) and antibody prodrugs (Probody).

Exclusivity of the Project. 4.1.1 Within three years after the effectiveness of this Agreement, Party B shall not develop on its own any monospecific antibodies antibody against the PD-L1 [***] target, nor shall it authorize any third party to the use of any sequences, cell lines, nanobodies, data, patented technology or other items; . Any new projects in conflict with the interests of this Project project shall be determined by the Parties Party A and Party B’s Affiliate through consultation and the Parties Party A and Party B’s Affiliate shall have the prior cooperation right. However, the exclusivity obligation provided for in this Article does not include shall exclude bispecific antibodies (simultaneously bind two different epitopes)antibodies, antibody conjugates (ADC), diagnostic antibodies, antibody-targeted nanoparticles (Nano-particles) and antibody prodrugs (Probody).